Form 4 Filing for Cadrenal Therapeutics, Inc.

This filing details stock transactions by Pham Quang X, CEO and Chairman of Cadrenal Therapeutics, Inc. (CVKD). On May 11, 2026, 6,476 shares of Common Stock were sold at a weighted average price of $5.76, with prices ranging from $5.47 to $6.12, under a Rule 10b5-1 trading arrangement. On May 12, 2026, 3,298 shares were sold at a weighted average price of $5.28, with prices ranging from $5.07 to $5.535. On May 28, 2026, 2,989 shares were sold at a weighted average price of $4.93, with prices ranging from $4.81 to $5.07. Following these transactions, the direct ownership of common stock decreased. The filing also corrects a previous understatement of indirectly owned shares held by The PVBQ Living Trust, with Quang Pham as Trustee, to 200,000 shares.